NASDAQ$ACET
Adicet Bio Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results and provided business updates for the second quarter ended June 30, 2024.
Adicet Bio reported a net loss of $29.9 million for the second quarter of 2024, with cash and cash equivalents totaling $224.1 million as of June 30, 2024. The company is advancing its pipeline of allogeneic gamma delta T cell therapies, including ADI-001 for autoimmune diseases and ADI-270 for renal cell carcinoma.
- Expanded ADI-001 clinical development beyond lupus nephritis to include systemic lupus erythematosus, systemic sclerosis and ANCA associated vasculitis, following recent FDA IND clearances.
- Received IND clearance for ADI-270 for the treatment of patients with relapsed/refractory renal cell carcinoma.
- FDA granted Fast Track Designation for two product candidates.
- Maintained a strong balance sheet with $224.1 million in cash and cash equivalents as of June 30, 2024.
Headline financials
Revenue & EPS history
Adicet Bio · Revenue · Quarterly
$181K
Forward guidance
Adicet Bio anticipates several key milestones in the near future, including commencing enrollment in its Phase 1 clinical trial of ADI-001 in lupus nephritis in Q3 2024 and initiating the Phase 1 trial of ADI-270 in patients with RCC in Q4 2024.
Tailwinds
- Initiating Phase 1 clinical trial of ADI-001 in lupus nephritis in Q3 2024.
- Preliminary clinical data from ADI-001 Phase 1 study expected in the first half of 2025.
- Enrollment of SLE, SSc and AAV patients expected to commence in the second half of 2024.
- Initiating Phase 1 clinical trial of ADI-270 in RCC patients in Q4 2024.
- Preliminary clinical data from ADI-270 study expected in the first half of 2025.
Headwinds
- Clinical data from ADI-001 in lupus nephritis is subject to site initiation and patient enrollment.
- Clinical data from ADI-001 in SLE, SSc and AAV patients are anticipated during the first half of 2025, subject to site initiation and patient enrollment expectations.
- The initiation of ADI-270 Phase 1 clinical trial is contingent upon study initiation progress.
- Preliminary clinical data from the ADI-270 study is subject to site initiation and patient enrollment.
- Future results are subject to risks and uncertainties, including regulatory approvals, clinical study outcomes, and market conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+1.1%
Avg return
Earnings day
+1.2%
Avg return
5 days after
-5.0%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+29.7%
Q4 2021
Best reaction
-9.1%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | -5.3% | +1.4% | |
| Q4 2025 | -3.2% | -1.6% | -4.0% | |
| Q3 2025 | -3.6% | -6.4% | -22.6% | |
| Q1 2025 | -6.9% | -7.5% | -7.9% | |
| Q4 2024 | -2.3% | +15.0% | -33.8% | |
| Q3 2024 | +1.5% | -3.8% | -19.8% | |
| Q2 2024 | +7.9% | +20.5% | +20.5% | |
| Q1 2024 | -2.8% | +11.1% | +0.7% | |
| Q4 2023 | +9.7% | +12.3% | +3.8% | |
| Q3 2023 | -4.9% | -10.3% | +4.9% | |
| Q2 2023 | +6.8% | -2.7% | -23.2% | |
| Q1 2023 | +4.1% | -4.5% | -14.9% | |
| Q4 2022 | -3.1% | -19.5% | -29.5% | |
| Q3 2022 | +1.9% | +11.0% | +3.8% | |
| Q2 2022 | -9.1% | -11.0% | -4.9% | |
| Q1 2022 | +8.6% | +13.1% | +9.6% | |
| Q4 2021 | +29.7% | +31.0% | +37.6% | |
| Q3 2021 | +3.2% | +0.8% | +49.7% | |
| Q2 2021 | +8.1% | -5.9% | +6.4% | |
| Q1 2021 | +1.5% | +7.7% | -22.5% | |
| Q4 2020 | -0.7% | +6.2% | -11.2% | |
| Q3 2020 | +5.9% | +9.2% | +22.3% | |
| Q2 2020 | +0.4% | +4.4% | -17.3% | |
| Q1 2020 | +9.1% | +10.3% | +24.6% | |
| Q4 2019 | -8.5% | -17.1% | -6.0% | |
| Q3 2019 | -5.3% | +6.7% | -85.2% | |
| Q2 2019 | -3.5% | -3.7% | -22.2% | |
| Q1 2019 | -4.6% | -7.3% | +1.3% | |
| Q4 2018 | -8.3% | -10.8% | -23.3% | |
| Q3 2018 | -5.8% | -5.2% | -2.7% | |
| Q2 2018 | +5.1% | -0.9% | +9.3% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro